Electrophoretics Limited

Other

Nanogen Recognomics Gmbh

King's College London

Proteome Sciences Plc

Stefan Kienle

Karsten Kuhn

Richard Joubert

Juergen Schaefer

Christian Baumann

Norbert Windhab

Andrew Hugin Thompson

Richard R Anderson

Ian Hugo Pike

Malcolm Andrew Ward

Helen Louise Byers

Joseph M Sheridan

Jonathan R Heal

Christian Hamon

Markus Schweitzer

William D O Hamilton

Michael D Fiechtner

Simon Lovestone

Christoph Brücher

Jürgen Schäfer

Jules Westbrook

Abdul Hye

Petra Prefot

Stefan Raddatz

Eberhard Schneider

Marc Pignot

Wolfgang Becker

Harald Legner

Jill M Orwick

Josef Schwarz

Nikolai Woellmer

Stephen Lynham

Thorsten Prinz

Jochen Müller-Ibeler

Jochen Müller

Nikolai Wollmer

Nikolai WÖLLMER

Jill Orwick

Richard Anderson

The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.

Casein kinase 1 delta inhibitor

The present invention relates to a set of two or more mass labels. Each mass label comprises: X-L-M-Re; X is a reporter moiety having exact mass; L is a bond cleavable by collision in a mass spectrometer; M is a mass modifier; Re is a) a reactive functionality for attaching the mass label to an analyte or b) the analyte. Each mass label in the set has the same integer mass; wherein the set comprises two or more subsets of mass labels, each subset comprising one or more mass labels; wherein, when the subset comprises two or more mass labels, the exact mass of the reporter moiety X of each mass label in the subset is different from the exact mass of the reporter moiety X of the mass labels in the same subset and in all other subsets; each mass label is distinguishable by mass spectrometry.

Isobaric mass labels

A reactive mass label for labelling a biological molecule for detection by mass spectrometry, which label comprises a reactive functionality for labelling thiol groups or carbonyl groups. Also provided is a reactive mass label for labelling a biological molecule for detection by mass spectrometry, wherein the mass label comprises the following structure:X-L-M-S&#x2014;Rewherein X is a mass marker moiety, L is a cleavable linker, M is a mass normalization moiety, S is a mass series modifying group comprising the following group: wherein J is C&#x2550;O, K is NH, and n is 2 or J and K are both CHand n is 1, and wherein m is at least 1; and Re is a reactive functionality for attaching the mass label to a biological molecule.

Mass labels

A mass label for labelling and detecting a biological molecule by mass spectroscopy, which label comprises the following structure: X-L-M wherein X is a mass marker moiety comprising the following group: formula (I), wherein the cyclic unit is aromatic or aliphatic and comprises from 0-3 double bonds independently between any two adjacent atoms; each Z is independently N, N(R), C(R), CO, CO(R), C(R), O or S; X is N, C or C(R); each Ris independently H, a substituted or unsubstituted straight or branched C-Calkyl group, a substituted or unsubstituted aliphatic cyclic group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted heterocyclic group; and y is an integer from 0-10, L is a cleavable linker comprising an amide bond and M is a mass normalization moiety. 

Reactive mass labels

The present invention relates to methods of detecting renal transplant rejection and other forms of renal damage. Protein markers or renal damage are provided, along with assays for detecting said markers. Also provided are methods for identifying markers of renal damage.

Markers of renal transplant rejection and renal damage

Methods and compositions relating to Alzheimer's disease are provided. Specifically, proteins that are differentially expressed in the Alzheimer's disease state relative to their expression in the normal state are provided. Proteins associated with Alzheimer's disease are identified and described. Methods of diagnosis of Alzheimer's disease using the differentially expressed proteins are also provided, as are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.

Methods of diagnosing Alzheimer's disease

The present invention relates to conjugates of synthetic binding units and nucleic acids. The present invention also relates to methods for sorting and immobilizing nucleic acids on support materials using such conjugates by specific molecular addressing of the nucleic acids mediated by the synthetic binding systems. Particularly, the present invention also relates to novel methods of utilizing conjugates of synthetic binding units and nucleic acids to in active electronic array systems to produce novel array constructs from the conjugates, and the use of such constructs in various nucleic acid assay formats. In addition, the present invention relates to various novel forms of such conjugates, improved methods of making solid phase synthesized conjugates, and improved methods of conjugating pre-synthesized synthetic binding units and nucleic acids. The present invention also relates to the use of conjugates of synthetic binding units and nucleic acids as substrates for various enzymatic reactions, including nucleic acid amplification reactions.

Enzymatic modification of a nucleic acid-synthetic binding unit conjugate

Growing community of inventors

Frankfurt am Main, Germany

Stefan Kienle